

Supplement

Table S1. Pooled vaccine effectiveness against medically attended SARS-CoV-2 infection among older adults during the JN.1 lineage-predominant period, using 14 instead of 7 days as immunisation definition^a, VEBIS primary care study, Europe, 20 November 2023–1 March 2024

| Analysis | Time since vaccination | Cases | Controls | VE (95% CI) |
|--|------------------------|-------|----------|-------------|
| Adults aged ≥65 years | Unvaccinated | 145 | 980 | - |
| | Overall | 73 | 738 | 27 (1–47) |
| | 1–5 weeks | 16 | 128 | 48 (10–72) |
| | 6–11 weeks | 46 | 397 | 23 (-11–48) |
| | 12–20 weeks | 11 | 213 | 5 (-92–56) |
| Older adults part of the age-specific COVID-19 vaccination campaign ^b | Unvaccinated | 219 | 1574 | - |
| | Overall | 90 | 896 | 24 (0–43) |
| | 1–5 weeks | 18 | 154 | 49 (15–71) |
| | 6–11 weeks | 59 | 491 | 17 (-15–40) |
| | 12–20 weeks | 13 | 251 | 10 (-64–54) |

Abbreviations: VEBIS, Vaccine Effectiveness, Burden and Impact Studies; N, number; VE, vaccine effectiveness; CI, confidence interval.

^a This analysis results also in the study period starting 14 days after the COVID-19 vaccination campaigns, by country, not 7 days, as in the main analysis.

^b The age-specific recommendation for 2023/24 COVID-19 vaccination was among adults aged ≥50, ≥60 or ≥65 years, depending on study site (see Table 1).

Table S2. Pooled vaccine effectiveness against medically attended SARS-CoV-2 infection among older adults during the JN.1 lineage-predominant period, by monthly time since vaccination cutoffs, VEBIS primary care study, Europe, 20 November 2023–1 March 2024

| Analysis | Time since vaccination | Cases | Controls | VE (95% CI) |
|-----------------------|--|--------------|----------|-------------|
| Adults aged ≥65 years | Unvaccinated | 145 | 980 | - |
| | Overall | 75 | 753 | 28 (2–48) |
| | 7–29 days | 11 | 72 | 40 (-15–72) |
| | 30–59 days | 34 | 232 | 28 (-9–53) |
| | 60–89 days | 22 | 282 | 29 (-15–58) |
| | 90+ days | 8 | 167 | 5 (-110–61) |
| | Older adults part of the age-specific COVID-19 vaccination campaign ^a | Unvaccinated | 219 | 1574 |
| Overall | | 92 | 920 | 26 (3–44) |
| 7–29 days | | 13 | 91 | 38 (-13–68) |
| 30–59 days | | 41 | 289 | 27 (-5–50) |
| 60–89 days | | 29 | 342 | 23 (-17–51) |
| 90+ days | | 9 | 198 | 11 (-79–61) |

Abbreviations: VEBIS, Vaccine Effectiveness, Burden and Impact Studies; N, number; VE, vaccine effectiveness; CI, confidence interval.

^a The age-specific recommendation for 2023/24 COVID-19 vaccination was among adults aged ≥50, ≥60 or ≥65 years, depending on study site (see Table 1).